Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986278 in pulmonary fibrosis
CTR20213153Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of admilparant in pulmonary fibrosis (PF), idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), sponsored by Bristol Myers Squibb. Started Apr 2022; status: active.
02
Drugs
admilparant
03
Conditions
pulmonary fibrosis (PF)idiopathic pulmonary fibrosis (IPF)progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on CTR20213153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213153.